764742.fig.005a
(a)
764742.fig.005b
(b)
764742.fig.005c
(c)
764742.fig.005d
(d)
764742.fig.005e
(e)
764742.fig.005f
(f)
764742.fig.005g
(g)
764742.fig.005h
(h)
764742.fig.005i
(i)
764742.fig.005j
(j)
Figure 5: Changes in P-CREB staining in the DM following different morphine treatments ((a) group 1, naïve; (b) group 2, saline; (c) group 3, MorX1; (d) group 5, MorX8; (e) group 6, Esc; (f) group 7, PP24 h; (g) group 8, PM24 h; (h) group 9, PP7d; (i) group 10 PM7d) as determined by immunofluorescence (200X). Quantification of P-CREB (j). See Table 1 for details on the morphine treatment paradigm. ** versus saline injection, versus saline and 7 d placebo pellet.